

Eva Dombi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4944475/publications.pdf>

Version: 2024-02-01

61
papers

3,164
citations

172457
29
h-index

161849
54
g-index

61
all docs

61
docs citations

61
times ranked

3136
citing authors

#	ARTICLE	IF	CITATIONS
1	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. <i>Neuro-Oncology</i> , 2022, 24, 1978-1988.	1.2	14
2	Management of neurofibromatosis type 1-associated plexiform neurofibromas. <i>Neuro-Oncology</i> , 2022, 24, 1827-1844.	1.2	29
3	Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 11561-11561.	1.6	2
4	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	1.2	30
5	MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. <i>Oncogene</i> , 2021, 40, 951-963.	5.9	12
6	Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1. <i>Neuro-Oncology Advances</i> , 2021, 3, vda1116.	0.7	2
7	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	30.7	46
8	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametininib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	1.6	54
9	Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S111-S119.	1.1	6
10	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
11	Are Some Randomized Clinical Trials Impossible?. <i>Journal of Pediatric Orthopaedics</i> , 2021, 41, e90-e93.	1.2	5
12	The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa095.	0.7	15
13	Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2020, 26, 6112-6121.	7.0	13
14	<i>Cdkn2a</i> Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. <i>Cancer Research</i> , 2020, 80, 4720-4730.	0.9	25
15	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	27.0	360
16	Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. <i>Neuro-Oncology</i> , 2020, 22, 1368-1378.	1.2	37
17	A molecular basis for neurofibroma-associated skeletal manifestations in NF1. <i>Genetics in Medicine</i> , 2020, 22, 1786-1793.	2.4	12
18	Current status of MEK inhibitors in the treatment of plexiform neurofibromas. <i>Child's Nervous System</i> , 2020, 36, 2443-2452.	1.1	33

#	ARTICLE	IF	CITATIONS
19	Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2020, 38, 3612-3612.	1.6	12
20	Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. Journal of Neurosurgery, 2020, 133, 1516-1526.	1.6	20
21	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma, 2019, 2019, 1-8.	1.3	45
22	Cediranib phaseâ€” study in children with metastatic alveolar softâ€”part sarcoma (ASPS). Pediatric Blood and Cancer, 2019, 66, e27987.	1.5	11
23	Fascicle Sparing Capsular Resections of Atypical Neurofibromas in Neurofibromatosis 1. Neurosurgery, 2019, 66, .	1.1	3
24	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenaseâ€”Deficient Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 6302-6308.	7.0	13
25	RUNX represses <i>Pmp22</i> to drive neurofibromagenesis. Science Advances, 2019, 5, eaau8389.	10.3	11
26	Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. American Journal of Human Genetics, 2019, 104, 484-491.	6.2	56
27	Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1â€”associated atypical neurofibromas. Neuro-Oncology, 2019, 21, 981-992.	1.2	69
28	Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI Insight, 2019, 4, .	5.0	21
29	The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro-Oncology, 2018, 20, 818-825.	1.2	83
30	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Academic Radiology, 2018, 25, 144-152.	2.5	17
31	Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro-Oncology, 2018, 20, 1643-1651.	1.2	54
32	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research, 2018, 24, 753-765.	7.0	26
33	RARE-07. THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1. Neuro-Oncology, 2018, 20, vi237-vi237.	1.2	1
34	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Neuro-Oncology, 2018, 20, i143-i143.	1.2	14
35	Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology, 2018, 1, 158.	4.4	49
36	SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2018, 36, 10503-10503.	1.6	28

#	ARTICLE	IF	CITATIONS
37	Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology, 2018, 36, 10540-10540.	1.6	1
38	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-Oncology, 2017, 19, now158.	1.2	41
39	Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1. Ophthalmology, 2017, 124, 123-132.	5.2	68
40	Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib.. Journal of Clinical Oncology, 2017, 35, 10540-10540.	1.6	2
41	Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. New England Journal of Medicine, 2016, 375, 2550-2560.	27.0	486
42	Current whole-body MRI applications in the neurofibromatoses. Neurology, 2016, 87, S31-9.	1.1	65
43	Insertional Mutagenesis Identifies a STAT3/Arid1b/β2-catenin Pathway Driving Neurofibroma Initiation. Cell Reports, 2016, 14, 1979-1990.	6.4	55
44	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. Journal of Clinical Oncology, 2016, 34, 1669-1675.	1.6	92
45	Atypical neurofibromas in neurofibromatosis 1 (NF1): Clinical, imaging and pathologic characteristics.. Journal of Clinical Oncology, 2016, 34, 11035-11035.	1.6	2
46	SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).. Journal of Clinical Oncology, 2016, 34, 11053-11053.	1.6	19
47	Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology, 2016, 34, TPS2596-TPS2596.	1.6	1
48	Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2016, 34, TPS10586-TPS10586.	1.6	0
49	Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. American Journal of Medical Genetics, Part A, 2015, 167, 2103-2113.	1.2	72
50	Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatric Blood and Cancer, 2015, 62, 1709-1716.	1.5	59
51	Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging. Journal of Neuro-Oncology, 2015, 121, 209-215.	2.9	31
52	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro-Oncology, 2015, 17, 596-603.	1.2	118
53	Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. Frontiers in Oncology, 2014, 4, 324.	2.8	80
54	Puberty and Plexiform Neurofibroma Tumor Growth in Patients with Neurofibromatosis Type I. Journal of Pediatrics, 2014, 164, 620-624.	1.8	28

#	ARTICLE	IF	CITATIONS
55	¹⁸ F-fluorodeoxyglucose (FDG)-PET evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). <i>Pediatric Blood and Cancer</i> , 2013, 60, 59-64.	1.5	52
56	Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. <i>Acta Neuropathologica</i> , 2013, 125, 159-168.	7.7	104
57	Recommendations for imaging tumor response in neurofibromatosis clinical trials. <i>Neurology</i> , 2013, 81, S33-40.	1.1	107
58	Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 75.	2.7	99
59	Preclinical testing of Sorafenib and RAD001 in the <i>Nf1^{flox/flox};DhhCre</i> mouse model of plexiform neurofibroma using magnetic resonance imaging. <i>Pediatric Blood and Cancer</i> , 2012, 58, 173-180.	1.5	60
60	Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. <i>Neuro-Oncology</i> , 2008, 10, 593-598.	1.2	200
61	Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. <i>Computerized Medical Imaging and Graphics</i> , 2004, 28, 257-265.	5.8	75